Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation
Oncolytic virus therapy can increase the immunogenicity of tumors and remodel the immunosuppressive tumor microenvironment, leading to an increased antitumor response to immune-checkpoint inhibitors. Here, we investigated the therapeutic potential of G47Δ, a third-generation oncolytic herpes simplex...
Main Authors: | Kotaro Sugawara, Miwako Iwai, Hirotaka Ito, Minoru Tanaka, Yasuyuki Seto, Tomoki Todo |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-09-01
|
Series: | Molecular Therapy: Oncolytics |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S237277052100070X |
Similar Items
-
Efficacy of a Third-Generation Oncolytic Herpes Virus G47Δ in Advanced Stage Models of Human Gastric Cancer
by: Kotaro Sugawara, et al.
Published: (2020-06-01) -
Neoadjuvant Use of Oncolytic Herpes Virus G47Δ Enhances the Antitumor Efficacy of Radiofrequency Ablation
by: Tomoharu Yamada, et al.
Published: (2020-09-01) -
Oncolytic herpes virus G47Δ injected into tongue cancer swiftly traffics in lymphatics and suppresses metastasis
by: Toshihiro Uchihashi, et al.
Published: (2021-09-01) -
Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells
by: Dhaval S. Sanchala, et al.
Published: (2017-05-01) -
Prospect of Plasmacytoid Dendritic Cells in Enhancing Anti-Tumor Immunity of Oncolytic Herpes Viruses
by: Philipp Schuster, et al.
Published: (2019-05-01)